Pharmaceutical News

RSS

DKSH supports Pfizer’s expansion to Laos

DKSH Business Unit Healthcare, the leading partner for healthcare companies seeking to grow their businesses in Asia, has signed an agreement to provide marketing, sales, logistics, distribution, credit management and -collection services to Pfizer in Laos.

12 May 2015

European Investment Bank supports Bavarian Nordic’s development of Ebola and cancer vaccines

The European Investment Bank (EIB), the world’s largest multilateral bank, today reaffirmed its firm commitment to respond to the Ebola pandemic. The Bank has provided a EUR 50 million loan to Bavarian Nordic, an international biopharmaceutical company, for accelerated development of an Ebola vaccine with long-term efficacy. The financing is also backing research into vaccines for treating other infectious diseases and multiple cancer indications.

12 May 2015

CPhI Istanbul 2015 opens as Turkey continues to dominate the MENA pharma region

Turkey is fast emerging as a new hub for pharma manufacturing. This year, CPhI Istanbul will welcome more than 200 exhibitors from 23 Countries and over 4,000 visitors..

12 May 2015

Cardiome signs commercialization agreement with AOP for ESMOCARD products

Cardiome Pharma Corp. today announced that the company has entered a commercialization agreement with AOP Orphan Pharma to sell AOP's cardiovascular products, ESMOCARD and ESMOCARD LYO (esmolol hydrochloride) in Italy, France, Spain and Belgium.

12 May 2015

Study: Disrupting cancer pathway could extend benefits of new immunity-boosting drugs

Understanding how to overrule a signaling pathway that can cause treatments to fail in metastatic melanoma patients should help physicians extend the benefits of recently approved immunity-boosting drugs known as checkpoint inhibitors to more patients.

12 May 2015

Merck KGaA, Darmstadt, Germany granted FDA Fast Track designation for development of evofosfamide

Merck KGaA, Darmstadt, Germany, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials today announced that the U.S. Food and Drug Administration has granted Fast Track designation for the development of evofosfamide (previously known as TH-302), administered in combination with gemcitabine, for the treatment of previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer.

12 May 2015

9-Valent HPV vaccine can potentially prevent 80% of cervical cancers in the U.S.

The new 9-valent human papillomavirus vaccine, can potentially prevent 80 percent of cervical cancers in the United States, if given to all 11- or 12-year-old children before they are exposed to the virus.

12 May 2015

Experimental gene therapy holds promise against metastatic prostate cancer

Even with the best available treatments, the median survival of patients with metastatic, hormone-refractory prostate cancer is only two to three years. Driven by the need for more effective therapies for these patients, researchers at VCU Massey Cancer Center and the VCU Institute of Molecular Medicine have developed a unique approach that uses microscopic gas bubbles to deliver directly to the cancer a viral gene therapy in combination with an experimental drug that targets a specific gene driving the cancer's growth.

12 May 2015

Panacea Pharmaceuticals selects Goodwin to complete novel vaccine Fill / Finish project

Goodwin Biotechnology, Inc., a biological Contract Development and Manufacturing Organization that specializes in bioprocess development and GMP manufacturing of biopharmaceuticals utilizing Mammalian Cell Culture expression systems and Bioconjugation technologies, was selected by Panacea Pharmaceuticals, Inc. to complete a novel Fill / Finish project, as well as Quality Control release and stability testing for a therapeutic, nanoparticle cancer vaccine based on the Human Aspartyl (Asparaginyl) β-Hydroxylase (HAAH) tumor-specific protein to support Phase I clinical trials in patients with various solid tumor cancers.

11 May 2015

Overview of Blueprint Medicines' kinase drug discovery strategy published in JCI

Blueprint Medicines today announced that the Journal of Clinical Investigation published an overview of the Company's kinase drug discovery and development strategy. The publication underscores Blueprint Medicines' focus on identifying novel genomically defined disease drivers and the use of novel chemistry from its proprietary compound library to craft highly selective kinase inhibitors for new and difficult-to-drug kinase targets.

11 May 2015

Scientists identify key factors in parents' decision-making about HPV vaccination of daughters

Human Papillomavirus (HPV) is a leading cause of sexually transmitted diseases, with more than 70% of sexually active people getting the virus at least once in their lifetimes. Persistent infection with some HPV strains can lead to cervical cancer, the second most common cancer in women, as well as to head-and-neck and other types of cancer and anogenital warts in both men and women.

10 May 2015

Researchers identify promising combination strategy for treating glioblastomas

Therapies that specifically target mutations in a person's cancer have been much-heralded in recent years, yet cancer cells often find a way around them. To address this, researchers at University of California, San Diego School of Medicine and Moores Cancer Center identified a promising combinatorial approach to treating glioblastomas, the most common form of primary brain cancer.

10 May 2015

Experimental cancer drug shows promise against incurable paediatric brain cancer

US-Australian drug discovery company, Novogen Limited, in conjunction with Australian paediatric cancer researchers, released key pre-clinical data on experimental cancer drug-candidate, TRXE-009, confirming its potential to become an important new therapy against an incurable paediatric brain cancer called DIPG (diffuse intrinsic pontine glioma).

8 May 2015

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Australian biopharmaceutical company Specialised Therapeutics Australia and Helsinn, a Swiss group focused on building quality cancer care, announce that the Therapeutic Goods Administration has approved AKYNZEO for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy.

8 May 2015

Using mobile app to track intake of vitamin D and calcium

Vitamin D is essential for the maintenance of bone health and may be implicated in other chronic diseases, as well as immunity, but adults in Canada are consistently deficient in dietary vitamin D, by nearly 400 international units per day (IU/d) on average.

8 May 2015

Study confirms link between statin drugs and diabetes risk

In a database study of nearly 26,000 beneficiaries of Tricare, the military health system, those taking statin drugs to control their cholesterol were 87 percent more likely to develop diabetes.

8 May 2015

Cancer drugs get quick approvals despite little effect on patients, says York U researcher

Highly priced cancer drugs get rushed approvals despite poor trial methodology and little effect on the longevity of patients, cautions York University Professor Dr. Joel Lexchin in the School of Health Policy and Management.

8 May 2015

New compound offers longer lasting painkilling effects

Medications have long been used to treat pain caused by injury or chronic conditions. Unfortunately, most are short-term fixes or cause side effects that limit their use. Researchers at the University of Missouri have discovered a new compound that offers longer lasting painkilling effects, and shows promise as an alternative to current anesthetics.

7 May 2015

New epilepsy drug holds promise as Alzheimer's treatment

University of British Columbia researchers say a new epilepsy drug holds promise as a treatment for Alzheimer's disease.

7 May 2015

Cyclenium Pharma, Haplogen sign agreement to discover novel pharmaceutical candidates

Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the research and development of novel drug candidates based on its proprietary macrocyclic chemistry technology, and Haplogen GmbH, a biotechnology company developing anti-infective drugs, today announced the signing of a research agreement aimed at the discovery of novel pharmaceutical candidates in multiple disease areas.

7 May 2015

Pharmaceutical News

DKSH supports Pfizer’s expansion to Laos

European Investment Bank supports Bavarian Nordic’s development of Ebola and cancer vaccines

CPhI Istanbul 2015 opens as Turkey continues to dominate the MENA pharma region

Cardiome signs commercialization agreement with AOP for ESMOCARD products

Study: Disrupting cancer pathway could extend benefits of new immunity-boosting drugs

Merck KGaA, Darmstadt, Germany granted FDA Fast Track designation for development of evofosfamide

9-Valent HPV vaccine can potentially prevent 80% of cervical cancers in the U.S.

Experimental gene therapy holds promise against metastatic prostate cancer

Panacea Pharmaceuticals selects Goodwin to complete novel vaccine Fill / Finish project

Overview of Blueprint Medicines' kinase drug discovery strategy published in JCI

Scientists identify key factors in parents' decision-making about HPV vaccination of daughters

Researchers identify promising combination strategy for treating glioblastomas

Experimental cancer drug shows promise against incurable paediatric brain cancer

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Using mobile app to track intake of vitamin D and calcium

Study confirms link between statin drugs and diabetes risk

Cancer drugs get quick approvals despite little effect on patients, says York U researcher

New compound offers longer lasting painkilling effects

New epilepsy drug holds promise as Alzheimer's treatment

Cyclenium Pharma, Haplogen sign agreement to discover novel pharmaceutical candidates

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News